AU4211200A - Tyrosine kinase substrate (tks) proteins - Google Patents

Tyrosine kinase substrate (tks) proteins

Info

Publication number
AU4211200A
AU4211200A AU42112/00A AU4211200A AU4211200A AU 4211200 A AU4211200 A AU 4211200A AU 42112/00 A AU42112/00 A AU 42112/00A AU 4211200 A AU4211200 A AU 4211200A AU 4211200 A AU4211200 A AU 4211200A
Authority
AU
Australia
Prior art keywords
tks
proteins
tyrosine kinase
kinase substrate
substrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU42112/00A
Other languages
English (en)
Inventor
Sara A. Courtneidge
Huan Phan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of AU4211200A publication Critical patent/AU4211200A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU42112/00A 1999-04-09 2000-04-06 Tyrosine kinase substrate (tks) proteins Abandoned AU4211200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12849299P 1999-04-09 1999-04-09
US60128492 1999-04-09
PCT/US2000/009277 WO2000061750A2 (en) 1999-04-09 2000-04-06 TYROSINE KINASE SUBSTRATE (Tks) PROTEINS

Publications (1)

Publication Number Publication Date
AU4211200A true AU4211200A (en) 2000-11-14

Family

ID=22435608

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42112/00A Abandoned AU4211200A (en) 1999-04-09 2000-04-06 Tyrosine kinase substrate (tks) proteins

Country Status (6)

Country Link
US (1) US20060019294A1 (enExample)
EP (1) EP1175490A2 (enExample)
JP (1) JP2002541802A (enExample)
AU (1) AU4211200A (enExample)
CA (1) CA2365623A1 (enExample)
WO (1) WO2000061750A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009271335B2 (en) * 2008-06-23 2015-06-25 Revvity Health Sciences, Inc. Kinase substrates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2217641A1 (en) * 1995-04-07 1996-10-10 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same
DE19820190A1 (de) * 1998-04-28 1999-11-04 Metagen Gesellschaft Fuer Genomforschung Mbh Menschliche Nukleinsäuresequenzen aus Pankreas-Tumor

Also Published As

Publication number Publication date
US20060019294A1 (en) 2006-01-26
WO2000061750A2 (en) 2000-10-19
WO2000061750A3 (en) 2001-12-06
EP1175490A2 (en) 2002-01-30
WO2000061750A9 (en) 2002-06-20
CA2365623A1 (en) 2000-10-19
JP2002541802A (ja) 2002-12-10

Similar Documents

Publication Publication Date Title
AU8681798A (en) Imidazoquinoxaline protein tyrosine kinase inhibitors
AU2437900A (en) Piperidinylquinolines as protein tyrosine kinase inhibitors
AU8681698A (en) Imidazoquinoxaline protein tyrosine kinase inhibitors
AU1371999A (en) Benzothiazole protein tyrosine kinase inhibitors
AU5173400A (en) Protein kinases
DE69913364D1 (en) Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
AU2002334355A1 (en) Protein tyrosine kinase inhibitors
PL351126A1 (en) Cyclic protein tyrosine kinase inhibitors
AU5468499A (en) 3-methylidenyl-2-indolinone modulators of protein kinase
AU5429199A (en) Modified green fluorescent protein
AU6998000A (en) Substituted indolinones as tyrosine kinase inhibitors
AU4065000A (en) Antisense modulation of p38 mitogen activated protein kinase expression
AUPQ346399A0 (en) Stable idle procedure
AU1315900A (en) Protein kinase homologs
AU2880400A (en) Tnf-related proteins
AU6045900A (en) Interaction-activated proteins
AU1945101A (en) Heat-relaxable substrates and arrays
AU2187301A (en) Protein kinase regulation
AU2576501A (en) Protein kinase inhibitors
AU3208699A (en) P40 protein acts as an oncogene
AU7687998A (en) Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
AU5284200A (en) Substrate trapping protein tyrosine phosphatases
AU2011599A (en) Mitogen-activated protein kinase kinase 7 (mkk7)
AU5706000A (en) Useful polypeptide
AU8375198A (en) Insulin receptor tyrosine kinase substrate

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase